Volume : 09, Issue : 05, May – 2022
Title:
19.MULTI-MODELLING TREATMENT OF ESOPHAGEAL AND GASTRO- ESOPHAGEAL CANCER
Authors :
Chanchal Ghoshi, Deepak Kurmi, Deepak Raikwar, Mr. Rupesh Jain*
Abstract :
Multiple specialists are involved in the treatment of esophageal and gastric cancers in order to improve patient outcomes. Starting with the initial staging evaluation, a multidisciplinary team approach ensures that all members are on board with the treatment strategy. Chemotherapy, radiation, surgery, and palliative therapies (endoscopic and surgical) are frequently used in the treatment of esophageal and gastric cancer, and close communication between professionals in these domains is required to guarantee effective clinical decision making. The Esophageal and Gastric Multidisciplinary Clinic at the University of Colorado was established to bring together all experts involved in the treatment of these diseases for a weekly meeting in order to provide patients with coordinated, tailored, and patient-centered care. This article explains the components and advantages of establishing a multidisciplinary programme to treat esophageal cancer patients.
Key words:Esophageal, Gastro- esophageal cancer, Multi-modelling, Treatment
Cite This Article:
Please cite this article in pressRupesh Jain et al,Multi-Modelling Treatment Of Esophageal And Gastro- Esophageal Cancer.,Indo Am. J. P. Sci, 2022; 09(5).,
Number of Downloads : 10
References:
1. Shapiro J, van Lanschot JJ, Hulshof MC et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long term results of a randomised controlled trial.LancetOncol2015;16:1090–1098.
2. Klevebro F, Alexandersson von Dobeln G, Wang N et al. A randomized clinical trial of neoadjuvant chemotherapy versus chemoradiotherapy for cancerof the oOesophagusorgastro-oesophagealjunction. AnnOncol 2016;27:660–667.
3. Reynolds JV. Randomised clinical trial of neoadjuvant and adjuvant chemotherapy (MAGIC Regimen) vs. neoadjuvant chemoradiation (CROSS protocol) in adenocarcinoma of the Oesophagus and oesophago-gastric junction. https ://clinical trials. gov/ct2/ show/ NCT01726452 (24 May 2016, datel ast accessed).
4. Alderson D, Langley RE, NankivellMGetal.Neoadjuvantchemotherapyforresectableoesophagealandjunctionaladenocarcinoma: results from the UK Medical Research Council randomized OEO5trial(ISRCTN01852072).JClinOncol2015;33:Abstr4002.
5. Hudis CA, Barlow WE, Costantino JP et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007;25:2127–2132.
6. Grigg OA, Farewell VT, Spiegel halter DJ. Use of risk-adjusted CUSUM and RSPRT charts for monitoring in medical contexts. Stat Methods Med Res 2003; 12(2): 147–170.
7. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.10.1056/NEJM199903183401101 10080844
8. Weusten B, Bisschops R, Coron E, et al . Endoscopic management of Barrett’s Oesophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy 2017;49:191-8.10.1055/s-0042-122140 28122386
9. LagergrenJ, BergströmR, NyrénO. Association between body mass and adenocarcinoma of the Oesophagus and gastric cardia. Ann Intern Med 1999;130:883-90.10.7326/0003-4819-130-11-199906010-00003 10375336
10. International Agency for Research on Cancer (IARC). Oespophagus. http://gco.iarc.fr/ today/data/factsheets/cancers/6-OOesophagus-fact-sheet.pdf For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe BMJ 2019;366:l4373
11. World Cancer Research Fund, American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. AICR, 2007. https:/ /www.wcrf.org/sites/default/files/english.pdf.
12. EngelLS, ChowW-H, VaughanTL, etal . Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003;95:1404-13.10.1093/jnci/djg047 13130116
13. Bjelakovic G, Nikolova D, Simonetti RG, GluudC. Antioxidant supplements for preventing gastrointestinal cancers. Cochrane Database Syst Rev 2008;(3):CD004183.18677777
14. O’Doherty MG, Cantwell MM, Murray LJ, Anderson LA, Abnet CCFINBAR Study Group. Dietary fat and meat intakes and risk of reflux esophagitis, Barrett’s Oesophagus and esophageal adenocarcinoma. Int J Cancer 2011;129:1493-502.10.1002/ijc.26108 21455992
15. Freedman ND, AbnetCC, LeitzmannMF, etal . A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol 2007;165:1424-33.10.1093/aje/kwm051 17420181
16. SiemiatyckiJ, KrewskiD, FrancoE, KaisermanM. Associations between cigarette smoking and each of 21 types of cancer: a multi-site case-control study. Int J Epidemiol 1995;24:504-14.10.1093/ije/24.3.504 7672889
17. FanY, YuanJ-M, WangR, GaoYT, YuMC. Alcohol, tobacco, and diet in relation to esophageal cancer: the Shanghai Cohort Study. Nutr Cancer 2008;60:354-63.10.1080/01635580701883011 18444169
18. CastellsaguéX, MuñozN, De StefaniE, etal . Independent and joint effects of tobacco smoking and alcohol drinking on the risk of esophageal cancer in men and women. Int J Cancer 1999;82:657-64.10.1002/(SICI)1097-0215(19990827)82:5<657::AID-IJC7>3.0.CO;2-C 10417762
19. LiyanageSS, RahmanB, RiddaI, etal . The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysis. PLoS One 2013;8:e69238.10.1371/journal.pone.0069238 23894436
20. SugarbakerDJ, EbrightM, KrasnaM. Overview: esophageal and proximal stomach malignancy. In: Sugarbaker DJ, ed. Adult chest surgery. McGraw-Hill Professional, 2009.
21. Alexandre L, Clark AB, Cheong E, Lewis MP, Hart AR. Systematic review: potential preventive effects of statins against oesophageal adenocarcinoma. Aliment Pharmacol Ther 2012;36:301-11.10.1111/j.1365-2036.2012.05194.x 22716127
22. Ross-Innes CS, Chettouh H, Achilleos A, et al. BEST2 study group. Risk stratification of Barrett’s Oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol Hepatol 2017;2:23-31.10.1016/S2468-1253(16)30118-2 28404010